1195687-62-7

Basic information

• Product Name: 2-[2-(1H-Pyrazol-4-yl)ethyl]-1H-isoindole-1,3(2H)-dione
• Synonyms: 2-[2-(1H-Pyrazol-4-yl)ethyl]-1H-isoindole-1,3(2H)-dione
• CAS NO: 1195687-62-7
• Molecular Formula: C13H11N3O2
• Molecular Weight: 241.24534
• Mol File: 1195687-62-7.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-[2-(1H-Pyrazol-4-yl)ethyl]-1H-isoindole-1,3(2H)-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 2-[2-(1H-Pyrazol-4-yl)ethyl]-1H-isoindole-1,3(2H)-dione(1195687-62-7)
• EPA Substance Registry System: 2-[2-(1H-Pyrazol-4-yl)ethyl]-1H-isoindole-1,3(2H)-dione(1195687-62-7)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 1195687-62-7(Hazardous Substances Data)

Usage

Structure

Contains an isoindole backbone with a pyrazole ring substitution

Derivative of

Isoindole

Functional Groups

Pyrazole ring

Potential Applications

Pharmaceutical industry
Chemical industry

Specific Uses

Not fully known

Properties

Requires further research
Implications need further investigation

Upstream product

• 438475-37-7 4-(2-chloroethyl)-1H-pyrazole 
• 1074-82-4 phthalimide potassium salt 
• 180207-57-2 2-(1H-pyrazol-4-yl)ethan-1-ol 
• 103433-17-6 4-(2-chloro-ethyl)-1H-pyrazole; hydrochloride 

Downstream Products

• 796845-58-4 2-(1-methyl-1H-pyrazol-4-yl)ethanamine 

Relevant articles and documents

1,2,5-oxadiazole derivative used as indoleamine 2,3-dioxygenase inhibitor

The invention belongs to the technical field of 1,2,5-oxadiazole derivatives, and particularly relates to a 1,2,5-oxadiazole derivative or a pharmaceutically acceptable salt thereof which is used as an indoleamine 2,3-dioxygenase inhibitor. The structure of the 1,2,5-oxadiazole derivative or the pharmaceutically acceptable salt thereof used as the IDO inhibitor is shown in the following formula I.The invention provides a general formula compound I with a novel structure. Experimental results show that some compounds have excellent IDO inhibitory activity and permeation performance at the sametime. The compound is expected to be marketed as a tumor molecular immunotherapeutic drug for cancer treatment.